Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Since the publication of the European Respiratory Society (ERS) task force reports on the management of preschool wheezing in 2008 and 2014, a large body of evidence has accumulated suggesting that the clinical phenotypes that were proposed (episodic (viral) wheezing and multiple-trigger wheezing) do not relate to underlying airway pathology and may not help determine response to treatment. Specifically, using clinical phenotypes alone may no longer be appropriate, and new approaches that can be used to inform clinical care are needed for future research. This ERS task force reviewed the literature published after 2008 related to preschool wheezing and has suggested that the criteria used to define wheezing disorders in preschool children should include age of diagnosis (0 to <6 years), confirmation of wheezing on at least one occasion, and more than one episode of wheezing ever. Furthermore, diagnosis and management may be improved by identifying treatable traits, including inflammatory biomarkers (blood eosinophils, aeroallergen sensitisation) associated with type-2 immunity and differential response to inhaled corticosteroids, lung function parameters and airway infection. However, more comprehensive use of biomarkers/treatable traits in predicting the response to treatment requires prospective validation. There is evidence that specific genetic traits may help guide management, but these must be adequately tested. In addition, the task force identified an absence of caregiver-reported outcomes, caregiver/self-management options and features that should prompt specialist referral for this age group. Priorities for future research include a focus on identifying 1) mechanisms driving preschool wheezing; 2) biomarkers of treatable traits and efficacy of interventions in those without allergic sensitisation/eosinophilia; 3) the need to include both objective outcomes and caregiver-reported outcomes in clinical trials; 4) the need for a suitable action plan for children with preschool wheezing; and 5) a definition of severe/difficult-to-treat preschool wheezing.

          Related collections

          Author and article information

          Journal
          Eur Respir J
          The European respiratory journal
          European Respiratory Society (ERS)
          1399-3003
          0903-1936
          Sep 2024
          : 64
          : 3
          Affiliations
          [1 ] Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
          [2 ] H. Makrinioti and V. Fainardi contributed equally to the manuscript.
          [3 ] Department of Medicine and Surgery, Paediatric Clinic, University of Parma, Parma, Italy.
          [4 ] Department of Pediatrics, University of Copenhagen, Copenhagen, Denmark.
          [5 ] National Heart and Lung Institute, Imperial College London, Imperial NIHR Biomedical Research Centre, and Centre for Paediatrics and Child Health, Imperial College London, London, UK.
          [6 ] Community Research Department, National Jewish Health, University of Colorado, Denver, CO, USA.
          [7 ] Patient Involvement and Engagement, European Lung Foundation, Sheffield, UK.
          [8 ] Department of Pediatric and Adolescent Medicine, University Hospital St Pölten, St Pölten, Austria.
          [9 ] Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria.
          [10 ] Translational Medicine Program, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
          [11 ] Department of Immunology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
          [12 ] Institute of Social and Preventive Medicine, Bern, Switzerland.
          [13 ] Department of Respiratory Medicine, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
          [14 ] Department of Pediatrics, Division of Respiratory Medicine and Allergology, Erasmus University Medical Center, Rotterdam, The Netherlands.
          [15 ] Usher Institute, University of Edinburgh, Edinburgh, UK.
          [16 ] Murdoch Childrens Research Institute, Melbourne, Australia.
          [17 ] SickKids Research Institute, Toronto, ON, Canada.
          [18 ] S. Saglani and P. Subbarao contributed equally to the manuscript.
          [19 ] National Heart and Lung Institute, Imperial College London, Imperial NIHR Biomedical Research Centre, and Centre for Paediatrics and Child Health, Imperial College London, London, UK s.saglani@imperial.ac.uk.
          Article
          13993003.00624-2024
          10.1183/13993003.00624-2024
          38843917
          9470412c-6a0a-4c20-8691-221c5a27115c
          History

          Comments

          Comment on this article